Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
Harold E BaysLouisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USAObjective: To evaluate the long-term safety, tolerability, and efficacy of colesevelam HCl (colesevelam) in type 2 diabetes mellitus patients receiving metformin monotherapy or metformin combination thera...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-05-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
| Online Access: | http://www.dovepress.com/long-term-52ndash78-weeks-treatment-with-colesevelam-hcl-added-to-metf-a9979 |